Focal Radiotherapy for Previously Treated Prostate Cancer Patients
ConditionLocally Recurrent Prostate Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorRoyal North Shore Hospital
About this trial
To examine the feasibility, safety and toxicity of focal stereotactic radiation treatment (SBRT) for locally recurrent prostate cancer.
Eligibility criteria
Qualifiers
Men > 4yrs from external beam radiotherapy (EBRT) meeting the Phoenix definition of biochemical failure or men > 5yrs from EBRT if neo-adjuvant and/or adjuvant androgen deprivation therapy (ADT) also used
Recurrence localised to less than 1 lobe of prostate on both PMSA and multi-parametric MRI (less than equal to cT2a)
Recurrence must be biopsy proven, with positive biopsies limited to the PET and MRI suspicious region.
Life expectancy at least 10yrs from time of SBRT
Disqualifiers
Recurrence in immediate proximity to rectum (unless able to have hydrogel)
Grade 3 or more toxicity from previous EBRT
Contra-indicated for fiducial insertion
GS 8,9 or 10 disease previously (relative - consider if decent disease free interval)
Trial design
Treatments tested in this trial
- Stereotactic Body Radiotherapy
Treatment groups
36 Participants
are divided into 3 treatment groupsSponsors and collaborators
Royal North Shore Hospital
Lead sponsor
Northern Sydney and Central Coast Area Health Service
Collaborator
Source ClinicalTrials.gov